Breast and liver cancer cells express various growth factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF). NFÎºB is the subject of intense study. NFÎºB is considered to be a transcription factor controlling expression of many proteins including VEGF and PDGF. Agents capable of suppressing NFÎºB activation have therapeutic promise and potential to inhibit carcinogenesis. The critical incidence rates of breast and liver carcinoma besides, these crucial biomarkers motivated our research group to design and synthesize novel drug like candidates with potential antitumor activity against breast and liver carcinoma. One of these potential candidates is pyrazolopyrimidine scaffold. Pyrazolo pyrimidines are fused heterocyclic ring systems which known as bio isosteres of adenine, that are necessary for every aspect of cell life. Current treatment strategies for different types of cancer are effective only in a portion of patients. Many factors influence the therapeutic effect, including genetic variations. This study aims to: Design and synthesis of novel pyrazolopyrimidine derivatives with potential antitumor activity. This study will include drug designing, cell culturing and molecular studies techniques to assists and prove our hypothesis. Cell lines culture (HepG2 and MCF-7 cells): to assess and investigate the potential gold role of these pathways targeting as a novel therapeutic strategies. Following drug treatment, cells lysates and nuclear extracts will be subjected to western blotting, qRT-PCR, Western blotting and/or ELISA to determine the different levels of the parameters for investigation of the drugs mechanisms of actions and toxicity studies.
Title: Novel Therapies Targeting Epigenetics and Autophagy in Breast and Liver cancer cell lines using Pyrazolopyrimidine Derivatives: Pharmacophore Modelling, Docking, Biological and Toxicological Evaluation
Dean of Scientific Research and Innovation
International Programs Coordinator / IT support
Mobile: 0020 10 205 262 67
Work: CITL/ Alex
Dr. Albashir Adel Youssef
mohamed youssef omar